Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

Autor: Sramila Aithal, Hendrik Tobias Arkenau, Muriel Siadak, Erica Stringer-Reasor, Mathilde Cancel, Erik Jakobsen, Erika Hamilton, Eva Harder Brix, Marco Colleoni, Cristiano Ferrario, Volkmar Mueller, Elisavet Paplomata, Amelia Zelnak, Frances M. Boyle, Elsa Curtit, S. Cold, Kendra DeBusk, Wentao Feng, Karen A. Gelmon, Margaret Block, Laurence Crouzet, Montserrat Muñoz-Mateu, Giuseppe Curigliano, Olwen Hahn, David Cameron, Andrew M Wardley, Nayyer Iqbal, Jorge Ramos, Teja Poosarla, Louis Fehrenbacher, Andrew Brenner

Publikováno v: Mueller, V, Wardley, A, Paplomata, E, Hamilton, E, Zelnak, A, Fehrenbacher, L, Jakobsen, E, Curtit, E, Boyle, F, Harder Brix, E, Brenner, A, Crouzet, L, Ferrario, C, Muñoz-Mateu, M, Arkenau, H T, Iqbal, N, Aithal, S, Block, M, Cold, S, Cancel, M, Hahn, O, Poosarla, T, Stringer-Reasor, E, Colleoni, M, Cameron, D, Curigliano, G, Siadak, M, DeBusk, K, Ramos, J, Feng, W & Gelmon, K 2021, ' Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial) ', European Journal of Cancer, vol. 153, pp. 223-233 . https://doi.org/10.1016/j.ejca.2021.05.025

Aims: In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer. We evaluated the impact of tucatinib on health-related q

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7721317814dc77c16d150d44866186d
https://findresearcher.sdu.dk:8443/ws/files/184128629/Open_Access_Version.pdf

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification

Autor: Sally Agersborg, Shiping Jiang, Robert Gasparini, Christopher Mixon, Gregory Hess, Sramila Aithal, Thanh Nguyen, Sucha Sudarsanam, Lawrence M. Weiss, Maher Albitar, Forrest Blocker, Wayne Chen

Publikováno v: Breast Cancer Research and Treatment

Purpose While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Alternative probes ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eeb76163463a3027d3bc418e30d657f
https://doi.org/10.1007/s10549-018-4755-5

Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients

Autor: Damien Mikael Hansra, Eugene R Ahn, John Edward McKnight, Haritha Pabbathi, Cynthia Lynch, Pamela A. Crilley, Ankur Rasik Parikh, Sramila Aithal, Amber Moran, Rebecca Rollins, Daniel W. Nixon, Maurie Markman, Ricardo H. Alvarez

Publikováno v: Journal of Clinical Oncology. 37:1098-1098

1098 Background: MBC is a rare entity comprising less than 1% of breast cancers [Siegel RL 2017]. Due to the low incidence of MBC, information about the genomic landscape of MBC is lacking. Here we describe detailed pathologic and genomic characteris

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db4716fc834f9a650a9214d911630610
https://doi.org/10.1200/jco.2019.37.15_suppl.1098

Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm)

Autor: Siraj M. Ali, Daniel W. Nixon, Dennis L. Citrin, Mary Ninan, Cynthia Lynch, Sramila Aithal, Damien Hansra, Joe Ensor, Amber Moran, Amanda Woodward, Eleanor Meisner, Rebecca Rollins, Ricardo H. Alvarez, S. Zook, Eugene R Ahn, Maurie Markman

Publikováno v: Journal of Clinical Oncology. 36:1074-1074

1074Background: A recent Phase III study in MBC with gBRCAm, olaparib monotherapy provided a statistical significant and clinically meaningful PFS benefit compared to standard physician of choice t...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d531eb22dea669dcfd9449bb51d05a45
https://doi.org/10.1200/jco.2018.36.15_suppl.1074

Retinal Vein Thrombosis as the Presenting Symptom of Essential Thrombocythemia

Autor: Allan D. Novetsky, Harry Marshak, Norman A. Saffra, Sramila Aithal, Yi-Wu Huang, Jason Eli Tache

Publikováno v: The American Journal of the Medical Sciences. 329:139-140

Visual loss resulting from retinal vascular disorders can be the presenting sign of serious systemic disease. Associations between retinal vein thrombosis and other systemic disorders have been well documented, but a comprehensive literature search f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724fbfd098c29f63ecbf4ea06674bc61
https://doi.org/10.1097/00000441-200503000-00005